Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
The purpose of this trial is to determinate the efficacy of Sunitinib in patients with renal cells carcinoma metastasic or locally avanced in patints not candidates to inicial curative nefrectomy.
Carcinoma Renal Cells
DRUG: Sunitinib
Progression-free survival, every 12 weeks
Global survival, At last contact date or death date|Response global, Every 12 weeks|Duration of response, Every 12 weeks|Security and tolerability of Sunitinib, Every 4 weeks
Study phase II in with one arm in patients with renal cells carcinoma.